title: The evaluation of immune responses that occur after HBV infection and HBV vaccination in hemodialysis patients.
abstract: The hepatitis B virus (HBV) vaccination never lose its importance; however, we did not get immune response with vaccination in some cases at the hemodialysis (HD) units. In this research, our aim was to evaluate antibody responses that constitute with natural ways and vaccination against HBV infection in chronic HD patients. In this retrospective cohort study (between 1999 February and 2001 December), 34 patients, 19 males and 15 females that were at the HD program, were enrolled. Patients were divided into two groups: group A, vaccination group (n = 15); and group B, anti-HBc IgG (+) cases (n = 19). We injected 40 microg of recombinant HBV vaccine into the deltoid muscle at 0, 1, 2, and 6 months. The anti-HBs levels, over 10 mIU/mL, were accepted for enough immunization. In group A, after vaccination 12 of 15 (80%) patients had seroconversion but later, in five of 12 (33.3%) patients, HBs-antibody became negative and in seven of 12 (46.7%) patients the positivity of HBs-antibody continued. However, in group B, 16 of 19 (66.7%) immune patients who faced HBV infection, it was established that antibody response continued (P > 0.05). The patients in group A who had anti-HCV negativity and serum albumin levels >/=3.5g/dL (7/0; P < 0.05) had too much antibody response against the vaccine. The difference of our research was that patients under 49 years old, patients who did not respond to HBV vaccine, were proportionally higher as compared to those from other researches. In conclusion, it was realized that the immune response of the HBV vaccine was low in the HD patients and it was affected by several factors such as gender, anti-HCV positivity and nutritional status. But, in spite of getting all universal precautions, still to face with new cases emphasizes the importance of the vaccination.
authors.affiliation: Department of Family Medicine, Dicle University Medical Faculty, Aile Hekimliği ABD, 21280 Diyarbakir, Turkey. ihkara13@hotmail.com
authors.forename: Ismail Hamdi
authors.initials: IH
authors.lastname: Kara
authors.forename: Mehmet Emin
authors.initials: ME
authors.lastname: Yilmaz
authors.forename: Ali
authors.initials: A
authors.lastname: Suner
authors.forename: Ali Kemal
authors.initials: AK
authors.lastname: Kadiroglu
authors.forename: Bunyamin
authors.initials: B
authors.lastname: Isikoglu
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D015331:Cohort Studies; D005260:Female; D006436:Hemodialysis Units, Hospital; D006509:Hepatitis B / Q000276:immunology* / Q000517:prevention & control*; D006510:Hepatitis B Antibodies / Q000097:blood; D017325:Hepatitis B Vaccines / Q000008:administration & dosage / Q000276:immunology*; D006515:Hepatitis B virus / Q000276:immunology; D018937:Hepatitis C Antibodies / Q000097:blood; D006801:Humans; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis; D051437:Renal Insufficiency / Q000150:complications* / Q000628:therapy; D012189:Retrospective Studies; D012709:Serum Albumin / Q000032:analysis; D012737:Sex Factors; D014614:Vaccines, Synthetic / Q000276:immunology
chemical_list: D006510:Hepatitis B Antibodies; D017325:Hepatitis B Vaccines; D018937:Hepatitis C Antibodies; D012709:Serum Albumin; D014614:Vaccines, Synthetic